Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEDOVA: OSE2101 +/- Pembrolizumab vs BSC in Recurrent Ovarian Cancer
NCT04713514Phase 2Active, not recruiting
- Sponsor
- ARCAGY
- Start
- Aug 2021
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Peptides, Therapeutic Vaccines
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of Tedopi in ovarian cancer (3 arms), sponsored by ARCAGY. Primary endpoint: Progression Free Survival up to 4 years. Started Aug 2021; status: active, not recruiting.
02
Drugs
Tedopi
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04713514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04713514.